| Features: Promote calcium and phosphorus absorption | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vitamin D3 (Cholecalciferol) - Major VITAL study stated Vit D did not reduce invasive cancer, but Secondary Analysis stated reduces the incidence of metastatic cancer at diagnosis. - Amount needed may depend on your BMI. - Vitamin D deficiency, as determined by serum 25(OH)D concentrations of less than 30 ng/mL, - Target achieving 80 ng/mL - Vitamin D may modulate oxidative stress markers. (ROS) - Nrf2 plays a key role in protecting cells against oxidative stress; this is modulated by vitamin D - Vitamin D has antioxidant and anti-inflammatory regulatory effects; whether supplementation alters response to specific chemotherapy regimens remains context-dependent and not firmly established. - excess Vit D can raise calcium and cause harm Vitamin D deficiency is generally defined as serum 25(OH)D <20 ng/mL (50 nmol/L), though some guidelines consider ≥30 ng/mL sufficient. - One recommendation is to get your level up to around 125 ng/ml (however not supported by consensus clinical trial evidence). - Chemo depletes Vitamin D levels so 10,000 IUs daily? – ask your doctor first. Typical maintenance dosing for most adults is 800–2000 IU/day; higher doses may be used short-term under medical supervision when correcting deficiency. After correction of vitamin D deficiency through loading doses of oral vitamin D (or safe sun exposure), adequate maintenance doses of vitamin D3 are needed. This can be achieved in approximately 90% of the adult population with vitamin D supplementation between 1000 to 4000 IU/day, 10,000 IU twice a week, or 50,000 IU twice a month [10,125]. On a population basis, such doses would allow approximately 97% of people to maintain their serum 25(OH)D concentrations above 30 ng/mL [19,126]. Others, such as persons with obesity, those with gastrointestinal disorders, and during pregnancy and lactation, are likely to require doses of 6,000 IU/day. Vitamin D, particularly its active form 1,25-dihydroxyvitamin D (calcitriol), exerts multiple biological effects that may influence cancer development and progression. Calcitriol has been reported to induce cell cycle arrest (often at the G0/G1 phase) and promote pro-apoptotic mechanisms in various cancer cell types. Inhibition of Angiogenesis: Some studies indicate that vitamin D can reduce the expression of pro-angiogenic factors, thereby potentially limiting the blood supply to tumors, which is necessary for tumor growth and metastasis. Effects on the Wnt/β-catenin Pathway: The Wnt/β-catenin signaling pathway, often dysregulated in several cancers (for example, colorectal cancer), may be modulated by vitamin D. Calcitriol has been shown in some models to inhibit β-catenin signaling, which is associated with decreased cell proliferation and tumor progression. Vitamin D may interact with other signaling pathways, including the PI3K/AKT/mTOR pathway, which is involved in cell survival and proliferation.
Time-Scale Flag (TSF): P / R / G
Clinical trial data suggest vitamin D supplementation effects may be attenuated in individuals with obesity, potentially due to pharmacokinetic and inflammatory differences.
|
| Source: |
| Type: |
| Vitamin D expression is decreased in: Breast, CRC, Prostate, Lung, Melanoma, GBM, Pancreatic cancer. (Poor prognosis, with decreased overall survival). Vitamin D expression is increased in RCC, Thyroid, Ovarian, Endometrial, Cervical cancers (***Better prognosis, with increased overall survival). See VDR and CYP27B1. CYP27B1 is the enzyme responsible for converting 25‐hydroxyvitamin D into its active form, 1,25‐dihydroxyvitamin D (calcitriol). As with VDR, CYP27B1 expression in tumors has been investigated for its potential prognostic significance in various cancers. What Vitamin D Reflects in Cancer Low 25(OH)D commonly indicates: -Reduced host resilience (frailty, sarcopenia risk) -Impaired immune regulation (innate and adaptive) -Higher inflammatory tone -Less favorable tumor microenvironment signaling Vitamin D status therefore integrates nutrition, inflammation, and immune competence. How Vitamin D Is Used Clinically A) Prognosis (Primary Use) -Low vitamin D associates with worse outcomes across several cancers (observational consistency). -Deficiency correlates with advanced disease and higher mortality. B) Treatment Tolerance & Supportive Care -Adequate levels support bone health, muscle function, and may reduce treatment-related complications. -Correction of deficiency is standard supportive care in many oncology settings. C) Immune Context (Adjunct) -VDR signaling modulates cytokine balance, dendritic cell function, and T-cell responses. -Status helps interpret immune readiness, but is not an immunotherapy selector. Vitamin D is a meaningful host-state biomarker in oncology. Low levels signal reduced physiological and immune reserve and are associated with poorer outcomes. While it does not guide tumor-specific therapy, maintaining adequate vitamin D is clinically relevant for prognosis, tolerance, and supportive care—making it an important component of the host biomarker layer. |
| - | Trial, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:167 Target#:851 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid